注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
DiaMedica Therapeutics Inc是一家臨床階段的生物製藥公司。該公司專注於開發神經和腎臟疾病的治療方法,例如急性缺血性中風(AIS)和慢性腎臟疾病(CKD)。該公司的主導產品DM199模仿天然存在的人類激肽釋放酶-1(KLK1)蛋白的行為,以保持和恢復中風受損組織的循環並改善整體腎功能。KLK1是一種絲氨酸蛋白酶或蛋白質,主要在腎臟、胰腺和唾液腺中產生。DM199療法有可能改善關鍵系統的循環和整體功能,以及減少炎症和氧化應激。該公司還擁有其他針對IgA腎病和患有CKD的非裔美國人的產品線。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
R. Michael Giuffre | 68 | 2010 | Independent Director |
Philip Bath | - | 2023 | Member of Stroke Advisory Board |
Richard D. Pilnik | 67 | 2009 | Independent Chairman |
Charles Herzog | - | - | Member of Kidney Scientific Advisory Board |
Aldo Peixoto | - | 2019 | Member of Kidney Scientific Advisory Board |
James T. Parsons | 59 | 2015 | Independent Director |
Dietrich John Pauls | 53 | 2005 | President, CEO & Director |
John Volpi | - | - | Member of Stroke Clinical Advisory Board |
Rajiv Agarwal | - | 2019 | Member of Kidney Scientific Advisory Board |
Glenn Matthew Chertow | - | 2019 | Member of Kidney Scientific Advisory Board |
Richard Edward Kuntz | 67 | 2023 | Independent Director |
Scott Eric Kasner | - | - | Member of Stroke Clinical Advisory Board |
George L. Bakris | - | 2019 | Member of Kidney Scientific Advisory Board |
Charles Pauling Semba | 63 | 2021 | Independent Director |
Tanya N. Lewis | 53 | 2023 | Independent Director |
Michael D. Hill | - | 2024 | Member of the Stroke Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核